Acrux Limited is gearing up for Phase III clinical trials of its female testosterone therapy, backed by FDA regulatory support and a sharp increase in licensing revenue, while navigating tight cash reserves with strategic funding efforts.
- March quarter revenue rises to $0.552 million
- FDA clears path for Phase III female testosterone trial
- Operating costs decline with R&D reprioritisation
- Cash reserves at $586k with 1.2 quarters funding
- Co-development partnerships targeted for commercialisation
Surge in Licensing Revenue Supports Strategic Pivot
Acrux Limited (ASX:ACR) reported a significant jump in revenue from product licensing and laboratory services, tallying $0.552 million in the March quarter and $3.222 million year-to-date, compared to just $0.168 million in the prior year. This growth underscores the company’s successful expansion of its topical generic pharmaceutical portfolio in the US and the emerging Laboratory and Development Services segment. The revenue boost not only validates Acrux’s focus on high-value transdermal intellectual property but also funds its pivot towards innovative hormone therapies.
However, the quarter’s sales were affected by resolved supply chain issues for Nitroglycerin ointment and delays in generic product listings for Dapsone gel, indicating ongoing operational challenges in the generics business. Acrux is actively seeking to expand its US footprint and explore international markets, leveraging its FDA registrations to build incremental revenue streams without heavy R&D investment. This strategy aligns with the company’s prior moves to optimise its portfolio, including divesting non-core assets to sharpen focus on hormone replacement therapies topical generics portfolio.
FDA Greenlights Phase III Female Testosterone Trial
The headline development for Acrux is the FDA’s regulatory clarity supporting the commencement of Phase III clinical trials for its female testosterone product. This therapy targets Hypoactive Sexual Desire Dysfunction (HSDD) in menopausal women, an unmet medical need with no currently approved treatments in the US. Acrux’s proprietary Metered Dose Transdermal Spray (MDTS) delivery system, already proven in other hormone replacement products, is positioned as a patient-preferred alternative to traditional patches.
Having completed Phase I and II trials internally, the company is now preparing for Phase III and pursuing co-development partnerships with multinational pharmaceutical firms experienced in clinical trial execution and global hormone therapy markets. CEO John Warmbrunn emphasised the generational opportunity this represents, highlighting positive feedback from potential partners and the strategic advantage of Acrux’s Patchless Patch™ technology. This regulatory milestone builds on the company’s earlier strategic shift to female testosterone, as detailed in its recent co-development strategy announcement co-development strategy.
Cost Discipline Amid Reprioritised R&D
Operating expenditure for the quarter was $1.370 million, down from prior periods, driven by lower staff costs and a focused reprioritisation of research and development activities. Acrux has concentrated its R&D spend on the female testosterone program at the expense of less promising topical generic projects. The FDA’s confirmation of the regulatory standing of completed trials has allowed the company to conduct this critical phase largely in-house, keeping external R&D expenses low.
Staff costs remain the largest expense but are trending downward due to natural attrition and a leaner workforce. A historical reclassification of $323,000 from administration to staff costs was noted, reflecting internal accounting adjustments rather than new spending. Acrux’s ability to maintain scientific talent is also supported by its Laboratory and Development Services, which recently won new contracts including work with Proteios Pty Ltd, a University of Sydney spinout, helping keep its team engaged and innovative.
Cash Position and Funding Strategies Under Scrutiny
Despite revenue gains, Acrux’s cash balance at quarter end stood at a modest $586,000, with total available funding including unused finance facilities at $1 million. This equates to just 1.2 quarters of runway at current operating cash burn, underscoring the urgency of securing additional capital. The company has received advances from Radium Capital against its Research and Development Tax Incentive Rebate, totalling $950,000 for FY27 to date, which provide short-term relief.
Acrux is actively pursuing several strategic options to ensure sufficient capital for ongoing operations and the costly Phase III clinical trial program. The company’s ability to execute at least one strategic transaction will be critical to maintaining momentum. This funding tightrope adds a layer of risk to the promising clinical and commercial developments, highlighting the need for investors to watch forthcoming capital initiatives closely R&D Tax Incentive advances.
Bottom Line?
Acrux’s FDA-backed Phase III trial for female testosterone is a pivotal step, but tight cash reserves mean the company’s near-term success hinges on securing additional funding and strategic partnerships.
Questions in the middle?
- How swiftly can Acrux secure a co-development partner to share Phase III trial costs and commercialisation risks?
- Will the company’s topical generics portfolio continue to generate steady revenue amid supply and listing challenges?
- Can Acrux’s Laboratory and Development Services segment scale to provide meaningful non-dilutive revenue?